Posted by Michael Wonder on 18 Nov 2019
Seelos Therapeutics receives FDA fast track designation for intranasal racemic ketamine (SLS-002)
18 November 2019 - Seelos Therapeutics today announced the U.S. FDA has granted fast track designation to its new, investigational intranasal racemic ketamine program, SLS-002, for the treatment of acute suicidal ideation and behaviour in patients with major depressive disorder.
Data from a Phase I study of SLS-002 to evaluate the pharmacokinetics, pharmacodynamics, and drug-drug interactions is expected in the first quarter of 2020.
